A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs

Vaccine

Volumn 26, Issue 5, 2008, Pages 623-638

  Giunchetti, Rodolfo Cordeiro ^a,b   Corrêa Oliveira, Rodrigo ^b   Martins Filho, Olindo Assis ^b   Teixeira Carvalho, Andréa ^a,b   Roatt, Bruno Mendes ^a   Aguiar Soares, Rodrigo Dian de Oliveira ^a   Coura Vital, Wendel ^a   Abreu, Raquel Tropia de ^a   Malaquias, Luiz Cosme Cotta ^c   Gontijo, Nelder Figueiredo ^d   Brodskyn, Cláudia ^b   Oliveira, Camila Indiani de ^b   Costa, Dirceu Joaquim ^b   de Lana, Marta ^a   Reis, Alexandre Barbosa ^a,b  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSIDADE VALE DO RIO DOCE   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Canine visceral leishmaniasis; Cell and humoral immune response; Flow cytometry

Indexed keywords

ADJUVANT; COMPLEMENT COMPONENT C3D RECEPTOR; LEISHMANIA VACCINE; SALIVA PROTEIN; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOG; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPHENOTYPING; LEISHMANIA CHAGASI; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHODIDAE; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, CD5; B-LYMPHOCYTES; CROSS REACTIONS; DOG DISEASES; DOGS; FEMALE; INJECTIONS, SUBCUTANEOUS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LYMPHOCYTE COUNT; MALE; MOLECULAR WEIGHT; NITRIC OXIDE; PROTEINS; PSYCHODIDAE; RECEPTORS, COMPLEMENT 3D; SALIVA; SALIVARY GLANDS; SAPONINS; T-LYMPHOCYTES; TISSUE EXTRACTS;

EID: 37849036578     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.057     Document Type: Article

References (90)

1. Lainson R., and Shaw J.J. Epidemiology and ecology of leishmaniasis in Latin-America. Nature 273 5664 (1978) 595-600
2. Theodos C.M., Ribeiro J.M., and Titus R.G. Analysis of enhancing effect of sand fly saliva on Leishmania infection in mice. Infect Immun 59 5 (1991) 1592-1598
3. Lerner E.A., Ribeiro J.M., Nelson R.J., and Lerner M.R. Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly Lutzomyia longipalpis. J Biol Chem 266 17 (1991) 11234-11236
4. Charlab R., Valenzuela J.G., Rowton E.D., and Ribeiro J.M. Toward an understanding of the biochemical and pharmacological complexity of the saliva of a haematophagous sand fly Lutzomyia longipalpis. Proc Natl Acad Sci USA 96 26 (1999) 15155-15160
5. Gillespie R.D., Mbow M.L., and Titus R.G. The immunomodulatory factors of blood feeding arthropod saliva. Parasite Immunol 22 7 (2000) 319-331
6. Cavalcante R.R., Pereira M.H., and Gontijo N.F. Anti-complement activity in the saliva of phlebotomine sand flies and other haematophagous insects. Parasitology 127 1 (2003) 87-93
7. Titus R.G., Bishop J.V., and Mejia J.S. The immunomodulatory factors of arthropod saliva and the potential for these factors to serve as vaccine targets to prevent pathogen transmission. Parasite Immunol 28 4 (2006) 131-141
8. Titus R.G., and Ribeiro J.M. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 239 4845 (1988) 1306-1308
9. Samuelson J., Lerner E., Tesh R., and Titus R. A mouse model of Leishmania braziliensis braziliensis infection produced by coinjection with sand fly saliva. J Exp Med 173 1 (1991) 49-54
10. Warburg A., Saraiva E., Lanzaro G.C., Titus R.G., and Neva F. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Philos Trans R Soc B 345 1312 (1994) 223-230
11. Lima H.C., and Titus R.G. Effects of sand fly vector saliva on development of cutaneous lesions and the immune response to Leishmania braziliensis in BALB/c mice. Infect Immun 64 12 (1996) 5442-5445
12. Belkaid Y., Kamhawi S., Modi G., Valenzuela J., Noben-Trauth N., Rowton E., et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva pre-exposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188 10 (1998) 1941-1953
13. Kamhawi S., Belkaid Y., Modi G., Rowton E., and Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 290 5495 (2000) 1351-1354
14. Morris R.V., Shoemaker C.B., David J.R., Lanzaro G.C., and Titus R.G. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 167 9 (2001) 5226-5230
15. Valenzuela J.G., Belkaid Y., Garfield M.K., Mendez S., Kamhawi S., Rowton E.D., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 194 3 (2001) 331-342
16. da Silva V., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto RN). Vaccine 19 9-10 (2000) 1082-1092
17. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Gonçalo do Amarante RN). Vaccine 20 27-28 (2002) 3277-3284
18. Ramiro M.J., Zarate J.J., Hanke T., Rodriguez D., Rodriguez J.R., Esteban M., et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21 19-20 (2003) 2474-2484
19. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district I.R. Iran. Vaccine 22 29-30 (2004) 4097-4100
20. Lemesre J.L., Holzmuller P., Cavaleyra M., Goncalves R.B., Hottin G., and Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 23 22 (2005) 2825-2840
21. Nogueira F.S., Moreira M.A., Borja-Cabrera G.P., Santos F.N., Menz I., Parra L.E., et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 40 (2005) 4805-4810
22. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23 28 (2005) 3716-3725
23. Saraiva E.M., de Figueiredo B.A., Santos F.N., Borja-Cabrera G.P., Nico D., Souza L.O., et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 13 (2006) 2423-2431
24. Lemesre J.L., Holzmuller P., Goncalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 21 (2007) 4223-4234
25. Santos F.N., Borja-Cabrera G.P., Miyashiro L.M., Grechi J., Reis A.B., Moreira M.A., et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine. Vaccine 25 33 (2007) 6176-6190
26. Valenzuela J.G., Garfield M., Rowton E.D., and Pham V.M. Identification of the most abundant secreted proteins from the salivary glands of the sand fly Lutzomyia longipalpis, vector of Leishmania chagasi. J Exp Biol 207 21 (2004) 3717-3729
27. Ravindran R., and Ali N. Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis. Curr Mol Med 4 6 (2004) 697-709
28. Mayrink W., Genaro O., Silva J.C., da Costa R.T., Tafuri W.L., Toledo V.P., et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem Inst Oswaldo Cruz 91 6 (1996) 695-697
29. Lasri S., Sahibi H., Sadak A., Jaffe C.L., and Rhalem A. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes. Vet Res 30 5 (1999) 441-449
30. Giunchetti R.C., Correa-Oliveira R., Martins-Filho O., Teixeira-Carvalho A., Roatt B.M., Aguiar-Soares R.D.O., et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine 25 44 (2007) 7674-7686
31. Giunchetti RC, Reis AB, Silveira-Lemos D, Martins-Filho OA, Corrêa-Oliveira R, Bethony J, et al. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis. Res Vet Sci, doi:10.1016/j.rvsc.2007.09.008.
32. Deane L.M. Reservoirs of Leishmania donovani in Brazil. Rev Assoc Med Bras 7 (1961) 161-169
33. Abranches P., Silva-Pereira M.C., Conceicao-Silva F.M., Santos-Gomes G.M., and Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J Parasitol 77 4 (1991) 557-561
34. Hommel M., Jaffe C.L., Travi B., and Milon G. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann Trop Med Parasitol 89 Suppl. 1 (1995) 55-73
35. Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol 100 1-2 (2001) 87-103
36. Mauel J. Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2 3 (2002) 201-226
37. Brodskyn C., de Oliveira C.I., Barral A., and Barral-Netto M. Vaccines in leishmaniasis: advances in the last five years. Expert Rev Vaccines 2 5 (2003) 705-717
38. Modi G.B., and Tesh R.B. A simple technique for mass rearing Lutzomyia longipalpis and Phlebotomus papatasi (Diptera: Psychodidae) in the laboratory. J Med Entomol 20 5 (1983) 568-569
39. Borja-Cabrera G.P., Cruz-Mendes A., Paraguai de Souza E., Hashimoto-Okada L.Y., de Trivellato F.A., Kawasaki J.K., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 17-18 (2004) 2234-2243
40. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 32 (2003) 4668-4676
41. Oliveira-Freitas E., Casas C.P., Borja-Cabrera G.P., Santos F.N., Nico D., Souza L.O., et al. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 24 18 (2006) 3909-3920
42. Reis A.B., Teixeira-Carvalho A., Vale A.M., Marques M.J., Giunchetti R.C., Mayrink W., et al. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol 112 3-4 (2006) 102-116
43. Reis A.B., Martins-Filho O.A., Teixeira-Carvalho A., Carvalho M.G., Mayrink W., Franca-Silva J.C., et al. Parasite density and impaired biochemical/hematological status are associated with severe clinical aspects of canine visceral leishmaniasis. Res Vet, Sci 81 1 (2006) 68-75
44. Reis A.B., Carneiro C.M., Carvalho M.G., Teixeira-Carvalho A., Giunchetti R.C., Mayrink W., et al. Establishment of a microplate assay for flow cytometric assessment and it is use for the evaluation of age-related phenotypic changes in canine whole blood leukocytes. Vet Immunol Immunopathol 103 3-4 (2005) 173-185
45. 15N]-nitrate in biological fluids. Anal Biochem 126 1 (1982) 131-138
46. Gutman S.I., and Hollywood C.A. Simple, rapid method for determining nitrates and nitrites in biological fluids. Clin Chem 38 10 (1992) 2152
47. Keenan C.M., Hendricks L.D., Lightner L., Webster H.K., and Johnson A.J. Visceral leishmaniasis in the German shepherd dog. I. Infection, clinical disease, and clinical pathology. Vet Pathol 21 1 (1984) 74-79
48. Moreno J., and Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18 9 (2002) 399-405
49. Alvar J., Canavate C., Molina R., Moreno J., and Nieto J. Canine leishmaniasis. Adv Parasitol 57 (2004) 1-88
50. Chamizo C., Moreno J., and Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 103 1-2 (2005) 67-75
51. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., et al. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol 146 2 (2006) 303-311
52. Giunchetti R.C., Mayrink W., Genaro O., Carneiro C.M., Correa-Oliveira R., Martins-Filho O.A., et al. Relationship between canine visceral leishmaniosis and the Leishmania (Leishmania) chagasi burden in dermal inflammatory foci. J Comp Pathol 135 2-3 (2006) 100-107
53. Giunchetti R.C., Mayrink W., Carneiro C.M., Correa-Oliveira R., Martins-Filho O.A., Marques M.J., et al. Histopathological and immunohistochemical investigations of the hepatic compartment associated with parasitism and serum biochemical changes in canine visceral leishmaniasis. Res Vet Sci 84 2 (2008) 269-277
54. Giunchetti R.C., Martins-Filho O., Carneiro C.M., Mayrink W., Marques M.J., Tafuri W.L., et al. Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis. Vet Immunol Immunopathol 121 1 (2008) 23-33
55. Lage R.S., Oliveira G.C., Busek S.U., Guerra L.L., Giunchetti R.C., Correa-Oliveira R., et al. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol 115 1-2 (2007) 135-145
56. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniosis. Vet Parasitol 106 4 (2002) 315-324
57. Noli C., and Auxilia S.T. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16 4 (2005) 213-232
58. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 63 5 (1995) 2062-2069
59. Webb J.R., Kaufmann D., Campos-Neto A., and Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 157 11 (1996) 5034-5041
60. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 7 (1998) 3279-3289
61. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., and Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19 4-5 (2000) 423-430
62. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69 6 (2001) 4103-4108
63. Requena J.M., Iborra S., Carrion J., Alonso C., and Soto M. Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther 4 9 (2004) 1505-1517
64. Khamesipour A., Rafati S., Davoudi N., Maboudi F., and Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res 123 3 (2006) 423-438
65. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., et al. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania-infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet Immunol Immunopathol 106 3-4 (2005) 247-257
66. Panaro M.A., Acquafredda A., Lisi S., Lofrumento D.D., Mitolo V., Sisto M., et al. Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes. Comp Immunol Microbiol Infect Dis 24 3 (2001) 187-195
67. Kamhawi S. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect 2 14 (2000) 1765-1773
68. Mejia J.S., Bishop J.V., and Titus R.G. Is it possible to develop pan-arthropod vaccines?. Trends Parasitol 22 8 (2006) 367-370
69. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., and Johnson Jr. W.D. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76 (1985) 2066-2069
70. Peruhype-Magalhaes V., Martins-Filho O.A., Prata A., Silva Lde A., Rabello A., Teixeira-Carvalho A., et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146 (2006) 124-132
71. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8 20 (2003) 934-943
72. Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13 1-2 (1996) 1-55
73. Rajput Z.I., Hu S.H., Xiao C.W., and Arijo A.G. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 8 3 (2007) 153-161
74. Santos W.R., de Lima V.M., de Souza E.P., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 1-2 (2002) 30-43
75. Parra L.E., Borja-Cabrera G.P., Santos F.N., Souza L.O., Palatnik-de-Sousa C.B., and Menz I. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 12 (2007) 2180-2186
76. Gomes R.B., Brodskyn C., de Oliveira C.I., Costa J., Miranda J.C., Caldas A., et al. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J Infect Dis 186 10 (2002) 1530-1534
77. Anderson J.M., Oliveira F., Kamhawi S., Mans B.J., Reynoso D., Seitz A.E., et al. Comparative salivary gland transcriptomics of sandfly vectors of visceral leishmaniasis. BMC Genomics 7 52 (2006) 1-23
78. Kato H., Anderson J.M., Kamhawi S., Oliveira F., Lawyer P.G., Pham V.M., et al. High degree of conservancy among secreted salivary gland proteins from two geographically distant Phlebotomus duboscqi sandfly populations (Mali and Kenya). BMC Genomics 7 226 (2006) 1-21
79. Oliveira F., Kamhawi S., Seitz A.E., Pham V.M., Guigal P.M., Fischer L., et al. From transcriptome to immunome: identification of DTH inducing proteins from a Phlebotomus ariasi salivary gland cDNA library. Vaccine 24 3 (2006) 374-390
80. Bahia D., Gontijo N.F., Leon I.R., Perales J., Pereira M.H., Oliveira G., et al. Antibodies from dogs with canine visceral leishmaniasis recognise two proteins from the saliva of Lutzomyia longipalpis. Parasitol Res 100 3 (2007) 449-454
81. Barral A., Honda E., Caldas A., Costa J., Vinhas V., Rowton E.D., et al. Human immune response to sand fly salivary gland antigens: a useful epidemiological marker?. Am J Trop Med Hyg 62 6 (2000) 740-745
82. Andrade B.B., de Oliveira C.I., Brodskyn C.I., Barral A., and Barral-Netto M. Role of sand fly saliva in human and experimental leishmaniasis: current insights. Scand J Immunol 66 2-3 (2007) 122-127
83. Bourdoiseau G., Bonnefont C., Hoareau E., Boehringer C., Stolle T., and Chabanne L. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs. Vet Immunol Immunopathol 59 1-2 (1997) 21-30
84. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 186 9 (2002) 1314-1320
85. Day M.J. Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation. Vet Parasitol 147 1-2 (2007) 2-8
86. Pinelli E. Cytokines in canine visceral leishmaniasis. In: Schijns V.E.C.J., and Horzinek M.C. (Eds). Cytokines in veterinary medicine (1997), CAB International, Wallingford 217-247
87. Cobbold S., and Metcalfe S. Monoclonal antibodies that define canine homologues of human CD antigens: Summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens 43 3 (1994) 137-154
88. Whitley E.M., Bird A.C., Zucker K.E., and Wolfe L.G. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res 15 3 (1995) 923-929
89. Radosevich T.J., Seregina T., and Link C.J. Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure. Hum Gene Ther 14 18 (2003) 1765-1775
90. Titus R.G. Salivary gland lysate from the sand fly Lutzomyia longipalpis suppresses the immune response of mice to sheep red blood cells in vivo and concanavalin A in vitro. Exp Parasitol 89 1 (1998) 133-136